A novel small-molecule PPI inhibitor targeting integrin αvβ3-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice

Biomaterials

Volumn 98, Issue , 2016, Pages 131-142

  Park, Doori ^a   Park, Chan Won ^b   Choi, YoungJin ^b   Lin, Jingjing ^a   Seo, Dong Hyun ^d   Kim, Han Sung ^d   Lee, Soo Young ^a   Kang, In Cheol ^b,c  

^a Ewha Womans University   (South Korea)

^b Hoseo University   (South Korea)

^c Innopharmascreen Inc   (South Korea)

^d Yonsei University Wonju   (South Korea)

Author keywords

Bone resorption; In silico molecular docking simulation; Integrin v 3 OPN interface; Osteoclast inhibition; ProteoChip; Small molecule PPI inhibitor

Indexed keywords

DRUG PRODUCTS; LIBRARIES; MAMMALS; MOLECULAR MODELING; MOLECULES; PROTEINS;

BONE RESORPTION; INTEGRINS; MOLECULAR DOCKING SIMULATIONS; PROTEOCHIP; SMALL MOLECULES;

BONE;

1,4 NAPHTHOQUINONE DERIVATIVE; 6,7 DICHLORO 2,3,5,8 TETRAHYDROXY 1,4 NAPHTHOQUINONE; ACTIN; AGENTS AFFECTING PROTEIN METABOLISM; ARGINYLGLYCYLASPARTIC ACID; COLONY STIMULATING FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; LIGAND; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CELL; BONE DESTRUCTION; BONE MARROW DERIVED MACROPHAGE; BONE MASS; CALVARIA; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SCREENING; FEMALE; HYDROGEN BOND; IN VITRO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NEWBORN; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOSKELETON; DRUG EFFECTS; DRUG THERAPY; METABOLISM; MOLECULAR LIBRARY; OSTEOCLAST; OVARIECTOMY; PHARMACOLOGY; PREVENTION AND CONTROL; THERAPEUTIC USE;

ACTINS; ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CYTOSKELETON; FEMALE; INTEGRIN ALPHAVBETA3; LIGANDS; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; OSTEOCLASTS; OSTEOPONTIN; OVARIECTOMY; PROTEIN BINDING; PROTEIN INTERACTION MAPS; RANK LIGAND; SMALL MOLECULE LIBRARIES;

EID: 84966697301     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.05.007     Document Type: Article

References (62)

1. White A.W., Westwell A.D., Brahemi G. Protein-protein interactions as targets for small-molecule therapeutics in cancer. Expert Rev. Mol. Med. 2008, 19(10):e8.
2. Arkin M.R., Tang Y., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem. Biol. 2014, 21:1102-1114.
3. Falchi F., Caporuscio F., Recanatini M. Structure-based design of small-molecule protein-protein interaction modulators: the story so far. Future Med. Chem. 2014, 6:343-357.
4. Kim E.Y., Kang I.C. Protein chip-based dipeptidyl peptidase IV assay system. BioChip J. 2009, 3:249-253.
5. Park C.W., Kang I.C., Choi Y.J. Activity-based screening system for the discovery of neuraminidase inhibitors using protein chip technology. BioChip J. 2012, 6:133-138.
6. Kim E.Y., Choi Y.J., Park C.W., Kang I.C. Erkitinib, a novel EGFR tyrosine kinase inhibitor screened using a ProteoChip system from a phytochemical library. Biochem. Biophys. Res. Commun. 2009, 389:415-419.
7. Kim E.Y., Bang J.Y., Chang S.I., Kang I.C. A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by protein chip system as a potent angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2008, 377:1288-1293.
8. Choi Y.J., Kim E.Y., Lee Y.S., Han M.H., Kang I.C. Site-specific inhibition of integrin avb3-vitronectinassociation by a ser-asp-val sequence through anArg-Gly-Asp-binding site of the integrin. Proteomics 2010, 10:72-80.
9. Park C.W., Kang I.C. Protein chip-based GLP-1 receptor assay system. BioChip J. 2014, 8:234-239.
10. Lee J.K., Kang I.C. Analysis of Plk1-bora interaction using a protein chip system. BioChip J. 2013, 7:151-155.
11. Park C.W., Bang J.Y., Choi Y.J., Kang I.C. ProteoChip-based screening system of novel inhibitors against the interaction of VEGF165 and β-Amyloid1-42. BioChip J. 2011, 5:299-303.
12. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
13. Harada S., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
14. Kim H., Choi H.K., Shin J.H., Kim K.H., Huh J.Y., Lee S.A., et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J. Clin. Invest. 2009, 119:813-825.
15. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
16. Engleman V.W., Nickols G.A., Ross F.P., Horton M.A., Griggs D.W., Settle S.L., et al. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 1997, 99:2284-2292.
17. Yamamoto M., Fisher J.E., Gentile M., Seedor J.G., Leu C.T., Rodan S.B., et al. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 1998, 139:1411-1419.
18. Reinholt F.P., Hultenby K., Oldberg A., Heinegard D. Osteopontin-a possible anchor of osteoclasts to bone. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:4473-4475.
19. Faccio R., Novack D.V., Zallone A., Ross F.P., Teitelbaum S.L. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin. J. Cell. Biol. 2003, 162:499-509.
20. Saltel F., Chabadel A., Bonnelye E., Jurdic P. Actin cytoskeletal organisation in osteoclasts: a model to decipher transmigration and matrix degradation. Eur. J. Cell. Biol. 2008, 87:459-468.
21. Rousselle A.V., Heymann D. Osteoclastic acidification pathways during bone resorption. Bone 2002, 30:533-540.
22. Teitelbaum S.L., Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 2003, 4:638-649.
23. Rieman D.J., McClung H.A., Dodds R.A., Hwang S.M., Holmes M.W., James I.E., et al. Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 2001, 28:282-289.
24. Novack D.V., Teitelbaum S.L. The osteoclast: friend or foe?. Annu. Rev. Pathol. 2008, 3:457-484.
25. McHugh K.P., Hodivala-Dilke K., Zheng M.H., Namba N., Lam J., Novack D., et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 2000, 105:433-440.
26. Feng X., Novack D.V., Faccio R., Ory D.S., Aya K., Boyer M.I., et al. A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J. Clin. Invest. 2001, 107:1137-1144.
27. Arias-Salgado E.G., Lizano S., Sarkar S., Brugge J.S., Ginsberg M.H., Shattil S.J. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:13298-13302.
28. Duong L.T., Lakkakorpi P.T., Nakamura I., Machwate M., Nagy R.M., Rodan G.A. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J. Clin. Invest. 1998, 102:881-892.
29. Lakkakorpi P.T., Nakamura I., Nagy R.M., Parsons J.T., Rodan G.A., Duong L.T. Stable association of PYK2 and p130(Cas) in osteoclasts and their co-localization in the sealing zone. J. Biol. Chem. 1999, 274:4900-4907.
30. Sanjay A., Houghton A., Neff L., DiDomenico E., Bardelay C., Antoine E., et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell. Biol. 2001, 152:181-195.
31. Epple H., Cremasco V., Zhang K., Mao D., Longmore G.D., Faccio R. Phospholipase Cgamma2 modulates integrin signaling in the osteoclast by affecting the localization and activation of Src kinase. Mol. Cell. Biol. 2008, 28:3610-3622.
32. Nakamura I., Lipfert L., Rodan G.A., Le T.D. Convergence of alpha(v)beta(3) integrin- and macrophage colony stimulating factor-mediated signals on phospholipase Cgamma in prefusion osteoclasts. J. Cell. Biol. 2001, 152:361-373.
33. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47:1739-1749.
34. Choi H.K., Kim T.H., Jhon G.J., Lee S.Y. Reactive oxygen species regulate M-CSF-induced monocyte/macrophage proliferation through SHP1 oxidation. Cell. Signal 2011, 23:1633-1639.
35. Suda T., Jimi E., Nakamura I., Takahashi N. Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol. 1997, 282:223-235.
36. Zou W., Kitaura H., Reeve J., Long F., Tybulewicz V.L., Shattil S.J., et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J. Cell. Biol. 2007, 176:877-888.
37. Kadono Y., Okada F., Perchonock C., Jang H.D., Lee S.Y., Kim N., et al. Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep. 2005, 6:171-176.
38. Lee S.H., Rho J., Jeong D., Sul J.Y., Kim T., Kim N., et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat. Med. 2006, 12:1403-1409.
39. Lee S.K., Kalinowski J.F., Jacquin C., Adams D.J., Gronowicz G., Lorenzo J.A. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J. Bone Min. Res. 2006, 21:695-702.
40. Jang H.D., Shin J.H., Park D.R., Hong J.H., Yoon K., Ko R., et al. Inactivation of glycogen synthase kinase-3beta is required for osteoclast differentiation. J. Biol. Chem. 2011, 286:39043-39050.
41. Montero A., Okada Y., Tomita M., Ito M., Tsurukami H., Nakamura T., et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J. Clin. Invest. 2000, 105:1085-1093.
42. Aoki K., Saito H., Itzstein C., Ishiguro M., Shibata T., Blanque R., et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J. Clin. Invest. 2006, 116:1525-1534.
43. Faccio R., Teitelbaum S.L., Fujikawa K., Chappel J., Zallone A., Tybulewicz V.L., et al. Vav3 regulates osteoclast function and bone mass. Nat. Med. 2005, 11:284-290.
44. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it?. Am. J. Pathol. 2007, 170:427-435.
45. Bogan A.A., Thorn K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 1998, 280:1-9.
46. Lo Conte L., Chothia C., Janin J. The atomic structure ofprotein-protein recognition sites. J. Mol. Biol. 1999, 285:2177-2198.
47. Rudolph J. Inhibiting transient protein protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nat. Rev. Cancer 2007, 7:202-211.
48. DeLano W.L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol. 2002, 12:14-20.
49. Sidhu S.S., Fairbrother W.J., Deshayes K. Exploring protein-protein interactions with phage display. Chembiochem 2003, 4:14-25.
50. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 2007, 13:791-801.
51. Mundy G.R. Osteoporosis and inflammation. Nutr. Rev. 2007, 65:S147-S151.
52. Boyce B.F., Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther. 2007, 9:S1.
53. Cohen S. Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. Arthritis Rheum. 2006, 55:15-18.
54. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington KSm Kurahara C., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Min. Res. 2009, 24:182-195.
55. Lin Y.L., de Villiers W.J., Garvy B., Post S.R., Nagy T.R., et al. The effect of class a scavenger receptor deficiency in bone. J. Biol. Chem. 2007, 282:4653-4660.
56. Hodsman A.B., Bauer D.C., Demoster D.W., Dian L., Hanley D.A., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 2005, 26:688-703.
57. Horton M.A. The alpha v beta 3 integrin "vitronectin receptor". Int. J. Biochem. Cell. Biol. 1997, 29:721-725.
58. Horton M.A., Taylor M.L., Arnett T.R., Helfrich M.H. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell. Res. 1991, 195:368-375.
59. Fisher J.E., Caulfield M.P., Sato M., Quartuccio H.A., Gould R.J., Garsky V.M., et al. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. Endocrinology 1993, 132:1411-1413.
60. Gan Z.R., Gould R.J., Jacobs J.W., Friedman P.A., Polokoff M.A. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J. Biol. Chem. 1988, 263:19827-19832.
61. Gould R.J., Polokoff M.A., Friedman P.A., Huang T.F., Holt J.C., et al. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med. 1990, 195:168-171.
62. Sato M., Sardana M.K., Grasser W.A., Garsky V.M., Murray J.M., Gould R.J. Echistatin is a potent inhibitor of bone resorption in culture. J. Cell. Biol. 1990, 111:1713-1723.